Ed Campanaro

BG Medicine (United States) — United States

Medicine · Health Sciences

7h-index900citations12works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(8), COVID-19 Clinical Research Studies(5), Monoclonal and Polyclonal Antibodies Research(4), Antimicrobial Resistance in Staphylococcus(2), Biosimilars and Bioanalytical Methods(2)

Publications12 total

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
Clinical Infectious Diseases·2025· 8 citedOpen Access
P-2029. Results from a Phase 1 First in Human Study of Pemivibart: An Extended Half-Life Monoclonal Antibody (mAb)
Open Forum Infectious Diseases·2025Open Access
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
2024· 4 citedOpen Access
1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
Open Forum Infectious Diseases·2023· 2 citedOpen Access
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Open Forum Infectious Diseases·2023· 22 citedOpen Access
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Open Forum Infectious Diseases·2023· 13 citedOpen Access
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Infectious Diseases and Therapy·2023· 7 citedOpen Access
226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study
Open Forum Infectious Diseases·2022Open Access
633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
Open Forum Infectious Diseases·2021· 2 citedOpen Access
Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting <i>Staphylococcus aureus</i> Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers
Antimicrobial Agents and Chemotherapy·2019· 58 citedOpen Access
Randomized Controlled Trial of the Safety and Efficacy of Daptomycin versus Standard-of-Care Therapy for Management of Patients with Osteomyelitis Associated with Prosthetic Devices Undergoing Two-Stage Revision Arthroplasty
Antimicrobial Agents and Chemotherapy·2012· 91 citedOpen Access
The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections
Clinical Infectious Diseases·2004· 693 citedOpen Access

Frequent Co-authors

Deepali Gupta(9), Kristin Narayan(8), Peter Schmidt(8), Kathryn Mahoney(5), Anna Holmes(4), Yong Li(4), Ilker Yalcin(4), Pamela Hawn(4), Natalia Betancourt(4), Anne-Marie Phelan(3), Kazima Tosh(3), Ellie Hershberger(3), Lynn Connolly(3), Frank Engler(3), Amanda Copans(3), Zoltán Magyarics(2), Michael G. Ison(2), Myra W. Popejoy(2), M. Tzekova(2), Anita Das(2)